Reports Q4 revenue $1.97M, consensus $1.43M. "2022 was a transformative year for Pliant. We delivered positive interim data from our Phase 2a INTEGRIS-IPF trial, strengthened our financial position with our first follow-on financing and continued to advance our clinical- and early-stage portfolio. We are positioned to deliver multiple clinical catalysts in 2023," said Bernard Coulie, president and CEO of Pliant Therapeutics. "2023 has already been productive with the release of additional positive data from the INTEGRIS-IPF 320 mg cohort, where bexotegrast displayed a continued favorable safety profile and outperformed all lower dose cohorts on exploratory efficacy endpoints. We look forward to sharing additional clinical data readouts and portfolio milestones throughout the remainder of this year."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PLRX:
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
- Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics announces FDA clearance of IND application for PLN-101095
- Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
